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Figure 1: Image of sclerodactyly
(Slideshare, 2014)

Signs & Symptoms
Signs and symptoms of scleroderma
vary based on the subset of the disease,
but according to Dixit, Kalkur, Sattur,
Bornstein, & Melton (2016), they most
commonly include:
•Raynaud’s Phenomenon (one of the first
signs)
•Finger swelling, stiffness, or digital
ulcers
•Nailfold capillary changes
•Gastrointestinal reflux
•Fatigue

Scleroderma is not an inherited
disease; however, a history of familial
genetic autoimmune disorders is
thought to predispose individuals to the
development of the disease.
Environmental factors such as exposure
to vinyl chloride, silica, and some viral
and bacterial infections are thought to
trigger the onset of the disease.
Scleroderma is an autoimmune
disease related to highly specific
autoantibodies. Anti-centromere
antibodies are associated with limited
cutaneous scleroderma.
Antitopoisomerase antibodies are a
characteristic of the diffuse cutaneous
subset. While anti-RNA polymerase III
antibodies are also found in diffuse
cutaneous disease, they are associated
with the added risk of renal
involvement. Anti-Th/To antibodies are
linked to the limited cutaneous form
with pulmonary fibrosis and PM-SCL
antibodies specify scleroderma with
polymyositis and severe calcinosis. The
autoantibodies are used in confirming
diagnosis, predicting disease subset, and
potential organ involvement (Chighizola,
Raschi, Cesana, Borghi, & Meroni, 2015).

Antibody specificity is thought to
affect organ manifestations and
phenotype expression (Caetano,
Nihtyanova, Harvey, Ong, & Denton,
2016). According to Mitra, et al. (2015),
mediators in the pathophysiological
process of scleroderma include:
•Transforming growth factor-β (TGFβ): contributes to overproduction of
extracellular matrix proteins (ECM) by
fibroblasts and promotes differentiation
of dermal fibroblasts to myofibroblasts.
•Platelet derived growth factor
(PDGF): helps in overproduction of ECM
by fibroblasts
Microvascular damage has been
found to be an early indicator of the
disease process. Endothelial cells induce
vascular cell adhesion molecule (VCAM)1 expression, produce multiple cytokines
and chemokines, release vasoconstrictor
endothelin-1, and participate in the
remodeling of vascular structures
(Eckes, Moinzadeh, Sengle, Hunzelmann,
& Kreig, 2014). Basement membrane
thickening and duplication create
narrowing of the lumen of capillaries
which leads to loss of microvasculature.
A cascade of events triggers the
inflammatory response with fibrosis
often a result.

Caring for a patient struggling with the
diagnosis of scleroderma sparks interest into
the subject for those unfamiliar with the
disease. This presentation is provided to
further increase knowledge on the topic.
Scleroderma, which generically means
hardening of the skin, is a rare disease that
causes fibrosis of connective tissue resulting in
loss of effectiveness. Sclerosis is a
heterogenous, multisystem, multistage
disorder noted by variable expression in its
forms of presentation and progression of
disease (Masi & Medsger, 2015).
Scleroderma has two main subsets:
localized and systemic. Both subsets have
different patterns in which the disease can
follow. Localized scleroderma is mostly mild,
does not involve internal organs, and generally
consists of localized areas of skin or muscle. It
can be morphea, which consists of waxy
patches of skin; or linear, which involve a line
of hardened waxy skin either on limbs or
forehead. Systemic sclerosis (SSc) can be
diffuse or limited. SSc can involve muscle,
joints, skin, blood vessels, and internal organs
such as heart, lungs, gastrointestinal tract, and
the esophagus.

Skin and organ fibrosis are key
manifestations with SSc and the fingers are
always effected (Distler & Cozzio, 2016).
The diffuse form of SSc is a more rapidly
progressing subset of the disease in which it
is more likely for internal organs to be
involved. Limited scleroderma is
sometimes referred to as CREST syndrome,
the name being an acronym for the five
common features of the disease: calcinosis,
Raynaud’s phenomenon, esophageal
dysfunction, sclerodactyly, and
telangiectasia. SSc predominately affects
women ages 20-50 years of age and is
associated with increased morbidity and
mortality rates (Baron, 2016). Scleroderma
has no known specific cause; however, it
does involve an overproduction of collagen.
Localized scleroderma is more frequent in
children while systemic scleroderma is seen
more in adults. Although there are
treatments for symptoms of sclerosis, there
is no cure.

Significance of Pathophysiology
Understanding the pathophysiological underlaying of scleroderma has
significantly helped to identify individuals effected by the disease and label subsets.
It has also aided in the development of possible treatments that could potentially
delay the progression of the disease. Most research focuses on the blockage of
pathways and mediators that promote formation of fibroblasts. Although
experiments with mice have been successful, the same success has not been seen in
humans.

•Weight loss
•Musculoskeletal pain
•Extremity edema
•Skin thickening (usually most obvious
sign)
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Scleroderma: What is it and why discuss it?
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Presentation of Case
Contact with a patient in a medical office
demonstrates the following data:
•25-year-old Caucasian female, no comorbidities known to date
•Complaining of joint swelling, decreased
hand grip, nausea, and heartburn
•Familial history of hypertension,
diabetes, and maternal rheumatoid arthritis
•Further investigation reveals:
involuntary weight loss of 20 lbs. over last 23 months, cold/numb feeling in fingers when
in air-conditioned environment, and
shortness of breath with exertion
•Physical exam reveals: palpable hard
deposits around upper extremity joints,
early developing finger flexion contractures,
and noted flat red marks to areas on face

Tests ordered with suspicion of
scleroderma diagnosis:
•Complete blood count (CBC)
•Antinuclear antibodies (ANA)
•Scl-70 antibody
•Comprehensive metabolic panel (CMP)
•Centromere antibody (ACA)
•Pulmonary function tests (PFTs)
•Chest x-ray

Conclusion
In conclusion, scleroderma is a rare disease but one associated with multiple
complications and comorbidities. Increased knowledge of the signs and symptoms,
familial history of autoimmune disorders, subset identification, pathophysiological
process, and current treatment options are vital in the diagnosis and management of
scleroderma. Ongoing research into better symptom management, improved prognosis,
and possible cure are grounded in the pathological foundation of the disease. Healthcare
providers should be abreast on the latest research and best practices when delivering
care to their patients effected by the disease.
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Follow-up tests show:
•CBC and CMP within normal limits
•Positive ANA, ACA, and Scl-70
•Interstitial fibrosis noted on x-ray
•PFTs suggestive of fibrosis
Diagnosis: Limited scleroderma with
pulmonary fibrosis

Figure 2: Pulmonary fibrosis on chest x-ray
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